English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Treatment with diphenyl–pyrazole compound anle138b/c reveals that α-synuclein protects melanoma cells from autophagic cell death.

MPS-Authors
/persons/resource/persons146792

Turriani,  E.
Emeritus Group Laboratory of Cellular Dynamics, MPI for Biophysical Chemistry, Max Planck Society;

/persons/resource/persons45923

Ryazanov,  S.
Department of NMR-based Structural Biology, MPI for biophysical chemistry, Max Planck Society;

/persons/resource/persons15438

Leonov,  A.
Department of NMR-based Structural Biology, MPI for biophysical chemistry, Max Planck Society;

/persons/resource/persons15147

Griesinger,  C.       
Department of NMR-based Structural Biology, MPI for biophysical chemistry, Max Planck Society;

/persons/resource/persons197309

Outeiro,  Tiago Fleming
Experimental Neurodegeneration, Max Planck Institute of Experimental Medicine, Max Planck Society;

/persons/resource/persons14791

Arndt-Jovin,  D. J.
Emeritus Group Laboratory of Cellular Dynamics, MPI for Biophysical Chemistry, Max Planck Society;

/persons/resource/persons206048

Becker,  D.
Department of NMR-based Structural Biology, MPI for biophysical chemistry, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)

2451256.pdf
(Publisher version), 2MB

Supplementary Material (public)
There is no public supplementary material available
Citation

Turriani, E., Lázaro, D. F., Ryazanov, S., Leonov, A., Giese, A., Schön, M., et al. (2017). Treatment with diphenyl–pyrazole compound anle138b/c reveals that α-synuclein protects melanoma cells from autophagic cell death. Proceedings of the National Academy of Sciences of the United States of America, 114(25), E4971-E4977. doi:10.1073/pnas.1700200114.


Cite as: https://hdl.handle.net/11858/00-001M-0000-002D-5CED-1
Abstract
Recent epidemiological and clinical studies have reported a significantly increased risk for melanoma in people with Parkinson’s disease. Because no evidence could be obtained that genetic factors are the reason for the association between these two diseases, we hypothesized that of the three major Parkinson’s disease-related proteins—α-synuclein, LRRK2, and Parkin—α-synuclein might be a major link. Our data, presented here, demonstrate that α-synuclein promotes the survival of primary and metastatic melanoma cells, which is the exact opposite of the effect that α-synuclein has on dopaminergic neurons, where its accumulation causes neuronal dysfunction and death. Because this detrimental effect of α-synuclein on neurons can be rescued by the small molecule anle138b, we explored its effect on melanoma cells. We found that treatment with anle138b leads to massive melanoma cell death due to a major dysregulation of autophagy, suggesting that α-synuclein is highly beneficial to advanced melanoma because it ensures that autophagy is maintained at a homeostatic level that promotes and ensures the cell’s survival.